论文部分内容阅读
对２５例恶性肿瘤患者单独或配合化疗使用重组人白细胞介素－２（ｒＩＬ－２）的疗效进行临床观察。２５例中男性１５例，女性１０例。平均年龄５３．１岁。肺癌７例，乳腺癌５例，结肠癌４例，直肠癌３例，肝癌、胃癌各２例，肾癌、神经纤维肉瘤各１例，分别采用全身静脉、瘤内注射、体腔内注射、介入动脉灌注等途径给药。观察结果：完全缓解２例，部分缓解６例，稳定２０例，总有效率为２８．６％。表明ｒＩＬ－２对改善恶性肿瘤患者的生活质量有一定帮助与化疗配合能提高疗效，且毒副反应轻。
The efficacy of recombinant human interleukin-2 (rIL-2) in 25 patients with malignant tumors alone or in combination with chemotherapy was clinically observed. In 25 cases, there were 15 males and 10 females. The average age is 53.1 years old. There were 7 cases of lung cancer, 5 cases of breast cancer, 4 cases of colon cancer, 3 cases of rectal cancer, 2 cases of hepatocellular carcinoma and 2 cases of gastric cancer, 1 case of renal cell carcinoma and 1 case of neurofibrosarcoma. They were systemic vein, intratumoral injection, intracavity injection, and intervention respectively. Arterial infusion and other routes of administration. Observations: Complete remission in 2 cases, partial remission in 6 cases, stability in 20 cases, total effective rate was 28.6%. It was shown that rIL-2 can help improve the quality of life of patients with malignant tumors. The combination of chemotherapy and chemotherapy can improve the efficacy, and the side effects are mild.